Bryan Clegg is an associate in the Dallas office of Gibson, Dunn & Crutcher.  He practices in the firm’s Litigation Department.  Mr. Clegg has represented clients in complex commercial litigation involving merger and acquisition disputes, securities fraud class actions, breach of contract claims, common law fraud claims, and FTC actions.

Bryan has been recognized by The Best Lawyers in America© as “Ones to Watch” in Commercial Litigation (2021).

Prior to joining Gibson Dunn, Mr. Clegg served as a law clerk to the Honorable Catharina Haynes of the United States Court of Appeals for the Fifth Circuit.

Mr. Clegg earned his law degree magna cum laude from Southern Methodist University, where he served as Editor-in-Chief of the SMU Law Review and was inducted into the Order of the Coif.  While in law school, Mr. Clegg completed an internship with the Honorable Jorge A. Solis and an externship with the Honorable Barbara M.G. Lynn of the United States District Court for the Northern District of Texas.  He received his Bachelor of Arts with high honors from the University of Texas at Austin.

Mr. Clegg is admitted to practice in the State of Texas.

Representative Matters

• Litigating complex commercial claims and counterclaims involving breach of contract, fraud, and indemnity in federal district court on behalf of large infrastructure company.
• Representing global engineering and construction company in a securities fraud class action involving revenue recognition practices on fixed-price construction projects.
• Representing pharmaceutical company in a securities fraud class action involving FDA approval of a new product.
• Represented global payment technology company in federal district court involving novel breach of contract and subrogation claims stemming from a data breach.
• Defended financial technology company against FTC Act claims based on allegations of misleading consumer advertising.
• Secured favorable settlement for large energy company in a merger and acquisition dispute involving breach of contract and fraud claims over working capital adjustments to the purchase price.
• Defeated attempted hostile takeover of pharmaceutical company after securing a preliminary injunction based on misuse of confidential information in breach of a nondisclosure agreement.